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Abstract 
Since anthracyclines were introduced in the
treatment of non-Hodgkin’s lymphoma in the
late 1960s, they have been acknowledged as a
cornerstone in the management of the disease
and, in particular, of aggressive lymphomas.
The high efficacy of anthracycline-containing
regimens must, however, be balanced against
the drug-related toxicity, which mainly affects
the  cardiovascular  system  and  represents  a
major concern for clinicians, especially in the
treatment  of  elderly  patients.  Patients’  out-
comes could be further improved, particularly
for those at high risk of cardiotoxicity, by sub-
stituting  liposomal  doxorubicin  for  conven-
tional doxorubicin. This approach has already
been tested and shown to be effective in sev-
eral cancers, especially in different subsets of
patients with diffuse large B-cell lymphoma.
The use of liposomal doxorubicin in combina-
tion regimens for other conditions, such as fol-
licular lymphoma and splenic marginal zone
lymphoma,  is  also  under  investigation,  and
early results are promising. 
Challenges in treating 
lymphoma
Non-Hodgkin’s lymphoma (NHL) is the most
common cancer of the lymphatic system and
represents the fifth most frequent cancer in
Western countries. Recent estimates of lym-
phoma incidence in Italy predict that there will
be nearly 15,000 new cases of NHL in 2011.
Diffuse large B-cell lymphoma (DLBCL) is the
most  common  aggressive  lymphoma,  repre-
senting more than 40% of new cases. Most im-
portantly, more than half of all patients with
NHL and DLBCL are older than 60 years.1-3
History of anthracycline use 
in NHL 
The history of treatment of aggressive NHL
started more than 50 years ago, with the use of
alkylators as single agents, with disappointing
results. In 1969, the first antitumor antibiotic
–  doxorubicin  –  became  available  and,  over
time, clinical trials demonstrated that this was
the most effective single agent for the treat-
ment of NHL. Subsequently, the combination
treatment  of  cyclophosphamide,  hydroxy-
daunorubicin  (doxorubicin),  vincristine,  and
prednisone (CHOP) was found to be a highly
effective treatment for aggressive NHL and be-
came the gold standard.4 In addition, reduction
of the inter-treatment interval,5 and the addi-
tion of rituximab to CHOP (R-CHOP)6-8 were
both found to improve patient outcomes. 
At present, the R-CHOP combination given
every 3 weeks is the standard treatment for
DLBCL  in  elderly  patients  and  is  associated
with  a  5-year  overall  survival  rate  of  about
60%.7 The transferability of R-CHOP from clin-
ical trials to practical management of elderly
patients with DLBCL is, however, still an issue.
The R-CHOP regimen is often poorly tolerated
in elderly patients, which necessitates dose re-
ductions that may result in a lower response
and  cure  rate  compared  with  younger  pa-
tients.9 Moreover, treatment-related mortality
for this therapy is close to 6%, and cardiologic
toxicity induced by doxorubicin remains a con-
cern  for  clinicians.10-12 Different  strategies
have been adopted in an attempt to reduce an-
thracycline-induced toxicity. These include the
design of combination regimens with reduced
drug  doses,9,13-15 a  maintained  anthracycline
dose  but  with  the  addition  of  cardioprotec-
tants,16,17 or the use of liposome-encapsulated
anthracyclines.18,19
Non-pegylated  liposomal  doxorubicin
(NPLD) has a shorter circulation time than its
pegylated counterpart.20 Animal data showed
that NPLD reduced drug delivery to the my-
ocardium and increased delivery to the liver,
spleen, and bone marrow.21 Significantly, this
pharmacokinetic profile is associated with re-
duced  myelosuppression,19 gastrointestinal
toxicity,18 and  risk  of  cardiotoxicity,20 when
compared  with  standard  formulations.  Inter-
estingly, research on the delivery of liposomal
formulations to different tissues also showed
that  their  entry  into  the  spleen  and  bone
marrow could be increased if treatment was
preceded by the administration of empty lipo-
somes, which blocked delivery of ‘active lipo-
somes’ to the liver.22 This treatment technique
could perhaps be considered in order to further
improve the delivery of liposome-encapsulated
drugs to the desired targets. 
Initial results of liposomal 
doxorubicin replacing doxorubicin
in lymphoma chemotherapy 
The effects of substitution of liposomal dox-
orubicin into CHOP have now been demon-
strated in patients with NHL. In an early study,
NPLD was substituted into CHOP (to form the
COMP  combination  chemotherapy)  in  pa-
tients with acquired immune deficiency syn-
drome (AIDS)-related NHL. The results were
promising,  with  a  75%  complete  response
(CR) rate; the results were even more impres-
sive  considering  that  two-thirds  of  the  pa-
tients (67%) had an intermediate to high In-
ternational  Prognostic  Index  (IPI).23 This
COMP  combination  chemotherapy  was  also
shown to be effective in newly diagnosed ag-
gressive  NHL,  with  a  CR  rate  of  67.4%,  al-
though,  as  would  be  expected,  hematologic
toxicity was also high (95.8% grade III or IV
neutropenia).24 Pegylated  liposomal  doxoru-
bicin has also been substituted into R-CHOP
for  the  treatment  of  elderly  patients  with
DLBCL, and produced a CR rate of 59%.25
Liposomal doxorubicin in the 
R-COMP combination in patients 
at risk of cardiotoxicity
As liposomal doxorubicin is associated with
lower  cardiotoxicity,  this  treatment  could  be
considered for patients who might not be able
to  receive  conventional  doxorubicin  because
they are at risk of cardiac disease. Rigacci et
al. conducted a prospective study of R-COMP
therapy in patients at risk of cardiotoxicity be-
cause they had concurrent cardiac diseases or
had  been  pretreated  with  anthracyclines.26
There was a CR rate of 76% and an overall re-
sponse rate of 90%. Only one patient developed
an acute grade III cardiotoxicity. 
A  larger,  prospective  European  study,  in-
volving  several  centers  in  Italy,  Germany,
Spain, and the UK (the EUR018 trial), was
conducted  to  investigate  the  efficacy  of  R-
COMP  in  elderly  patients  with  aggressive
lymphoma.  Patients  were  aged  at  least  61
years, and some were more than 80 years old
– the median age was 72 years.27 More than
half of the patients (56%) had an IPI of 3 or
more,  the  median  baseline  left  ventricular
ejection  fraction  (LVEF)  was  61%,  and  the
dose intensity of NPLD was 85.3%. In the in-
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plete remission rate was 57%, and this in-
creased  to  66%  in  the  population  that  re-
ceived at least three cycles of treatment (ef-
ficacy population). Overall survival in the ITT
population was 72%, the failure-free survival,
which takes into account those patients who
left the study prematurely, was 40%, and pro-
gression-free  survival  was  around  70%
(Figure  1).  These  results  were  somewhat
better in the efficacy population (77%, 46%,
and 74%, respectively). Importantly, no sig-
nificant reduction in cardiac function and no
change in LVEF were apparent during treat-
ment (Figure 2), and the R-COMP regimen
was  not  associated  with  any  increase  in
acute cardiac toxicity. 
There are now studies of R-COMP ongoing
in patients with DLBCL who have cardiopathy
(the  HEART01  trial,  NCT01009970),  and  to
compare the cardiotoxicity of R-CHOP and R-
COMP (the NHL-14 trial, NCT00575406). 
Use of liposomal doxorubicin in
other treatment combinations 
Possible  next  steps  in  treatment  develop-
ment may be the substitution of liposomal dox-
orubicin into the combination of rituximab, cy-
clophosphamide,  epirubicin,  vinblastine,  and
prednisone (R-miniCEOP). This combination
has been investigated in the ANZINTER3 trial
(NCT01148446).  Preliminary  results  showed
that most patients older than 72 years with an
age-adjusted (aa)IPI of 0 or 1 could be treated
effectively with R-miniCEOP.15 There may be a
place for NPLD in this type of combination, in
an attempt to provide even better efficacy and
further reduce the cardiotoxicity of therapy in
this low-risk population. 
Use of anthracyclines in follicular
lymphoma 
A retrospective analysis was conducted on
633  patients  with  follicular  lymphoma  (FL)
who  received  anthracycline-containing  treat-
ment regimens and 128 patients who did not
receive anthracyclines. This analysis showed
longer overall survival (Figure 3) and failure-
free survival in patients who received anthra-
cyclines, compared with those who did not.28
Support for this result from a prospective, ran-
domized, controlled trial is now needed, and
recruitment has just finished for the FOLL05
study  (NCT00774826)  comparing  rituximab,
cyclophosphamide,  vincristine,  and  pred-
nisone (R-CVP) with R-CHOP and rituximab,
fludarabine, and mitoxantrone (R-FM) in 534
Figure 1. Kaplan-Meier analysis of the probability of (A) overall survival, (B) failure-free survival, and (C) progression-free survival in
elderly patients receiving rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine, and prednisone (R-COMP)
chemotherapy for diffuse large B-cell lymphoma (results from the EUR018 trial).27 From Luminari S et al. Nonpegylated liposomal dox-
orubicin (MyocetTM) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results
from the phase II EUR018 trial. Ann Oncol 2010;21:1492-9. Reprinted with permission from Oxford University Press. 
Figure  2.  Left  ventricular  ejec-
tion fraction (LVEF) from base-
line to end of treatment in elder-
ly  patients  receiving  rituximab,
cyclophosphamide, non-pegylat-
ed  liposomal  doxorubicin,  vin-
cristine,  and  prednisone  (R-
COMP)  chemothe  rapy  for  dif-
fuse  large  B-cell  lymphoma
(results  from  the  EUR018
trial).27 From Luminari S et al.
Nonpegylated  liposomal  dox-
orubicin  (MyocetTM)  combina-
tion  (R-COMP)  chemo  therapy
in  elderly  patients  with  diffuse
large  B-cell  lymphoma
(DLBCL): results from the phase
II  EUR018  trial.  Ann  Oncol
2010;21:1492-9. Reprinted with
permission  from  Oxford
University Press. 
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Articlepatients with stage II-IV newly diagnosed FL. If
this study demonstrates that R-CHOP is more
effective than R-CVP and R-FM, a next step
could be to substitute a less cardiotoxic lipo-
somal  doxorubicin  for  conventional  doxoru-
bicin in this combination. 
Use of liposomal doxorubicin in
splenic marginal zone lymphoma 
As it has been demonstrated that liposomal
doxorubicin  is  concentrated  in  the  spleen,
this may be an excellent therapy for patients
with indolent B-cell lymphomas in this organ.
The recently completed R-COMP05 trial is a
Phase II study of R-COMP in the treatment of
splenic  marginal  zone  B-cell  lymphoma.  All
patients received three courses of R-COMP,
and those who responded to this treatment
were offered three additional courses. A total
of  63  patients  were  enrolled,  two  of  whom
were excluded before centralized review, and
the diagnosis was confirmed for 51 patients –
a  centralized  review  is  essential  in  these
sorts of studies, as the risk of misdiagnosis is
high.  Preliminary  results  of  the  study  indi-
cated  promising  outcomes  with  R-COMP
therapy in this group of patients.29
Conclusions 
Anthracyclines,  particularly  doxorubicin,
have a long-standing and important role in the
management of NHL. The CHOP and subse-
quently  R-CHOP  regimens  are  standard
therapy for this condition. More recently, the
substitution of NPLD into this treatment reg-
imen, to form R-COMP, has allowed the treat-
ment of patients who could not previously re-
ceive  R-CHOP  because  they  had  already  re-
ceived anthracycline therapy or were at risk of
cardiotoxicity. In addition, the use of liposomal
doxorubicin in other lymphomas, such as FL
and splenic marginal zone lymphoma, is cur-
rently under investigation and showing prom-
ising  results.  Using  liposomal  doxorubicin,
therefore, it seems likely that in the future it
should be possible to treat more and a greater
variety of patients with curative intent than in
the past. How such treatments will compare to
bendamustine is unknown.
References 
1. Luminari S, Cesaretti M, Rashid I, et al. Inci-
dence, clinical characteristics and survival of
malignant  lymphomas:  a  population-based
study  from  a  cancer  registry  in  northern
Italy. Hematol Oncol 2007;25:189-97.
2. Maartense E, Hermans J, Kluin-Nelemans
JC, et al. Elderly patients with non-Hodgkin’s
lymphoma: population-based results in The
Netherlands. Ann Oncol 1998;9:1219-27.
3. Thieblemont  C,  Coiffier  B.  Lymphoma  in
older patients. J Clin Oncol 2007;25:1916-23.
4. Fisher  RI,  Gaynor  ER,  Dahlberg  S,  et  al.
Comparison of a standard regimen (CHOP)
with  three  intensive  chemotherapy  regi-
mens  for  advanced  non-Hodgkin’s  lym-
phoma. N Engl J Med 1993;328:1002-6.
5. Pfreundschuh M, Trumper L, Kloess M, et al.
Two-weekly or 3-weekly CHOP chemothera-
py with or without etoposide for the treat-
ment  of  elderly  patients  with  aggressive
lymphomas: results of the NHL-B2 trial of
the DSHNHL. Blood 2004;104:634-41.
6. Coiffier B, Thieblemont C, Van Den Neste
E, et al. Long-term outcome of patients in
the  LNH-98.5  trial,  the  first  randomized
study comparing rituximab-CHOP to stan-
dard  CHOP  chemotherapy  in  DLBCL  pa-
tients: a study by the Groupe d’Etudes des
Lymphomes de l’Adulte. Blood 2010; 116:
2040-5.
7. Feugier  P,  Van  Hoof  A,  Sebban  C,  et  al.
Long-term results of the R-CHOP study in
the treatment of elderly patients with dif-
fuse large B-cell lymphoma: a study by the
Groupe  d’Etude  des  Lymphomes  de
l’Adulte. J Clin Oncol 2005;23:4117-26.
8. Pfreundschuh M, Schubert J, Ziepert M, et
al.  Six  versus  eight  cycles  of  bi-weekly
CHOP-14  with  or  without  rituximab  in
elderly patients with aggressive CD20+ B-
cell lymphomas: a randomised controlled
trial (RICOVER-60). Lancet Oncol 2008;9:
105-16.
9. Dixon DO, Neilan B, Jones SE, et al. Effect
of age on therapeutic outcome in advanced
diffuse histiocytic lymphoma: the South-
west  Oncology  Group  experience.  J  Clin
Oncol 1986;4:295-305.
10. Coiffier B, Lepage E, Briere J, et al. CHOP
chemotherapy  plus  rituximab  compared
with CHOP alone in elderly patients with
diffuse  large-B-cell  lymphoma.  N  Engl  J
Med 2002:346:235-42.
11. Green M. Anthracycline cardiotoxicity, no
longer an issue? Ann Oncol 1998;9:691-3.
12. Limat S, Demesmay K, Voillat L, et al. Early
cardiotoxicity of the CHOP regimen in ag-
gressive  non-Hodgkin’s  lymphoma.  Ann
Oncol 2003;14:277-81.
13. Bertini M, Boccomini C, Calvi R. The influ-
ence of advanced age on the treatment and
prognosis of diffuse large-cell lymphoma
(DLCL). Clin Lymphoma 2001:1:278-84.
14. Bertini M, Freilone R, Vitolo U, et al. The
treatment of elderly patients with aggres-
sive non-Hodgkin’s lymphomas: feasibility
and efficacy of an intensive multidrug reg-
imen. Leuk Lymphoma 1996;22:483-93.
15. Merli F, Luminari S, Tucci A, et al. R-CHOP
vs  R-MiniCEOP  in  elderly  patients  with
diffuse  large  B-cell  lymphoma  (B-DLCL)
prospectively  selected  by  a  multidimen-
sional  evaluation  scale:  preliminary  re-
sults of a randomized study performed by
Intergruppo Italiano Linfomi (IIL). Blood
2007;110:Abs 3429.
16. Swain SM, Vici P. The current and future
role of dexrazoxane as a cardioprotectant
in  anthracycline  treatment:  expert  panel
review.  J  Cancer  Res  Clin  Oncol  2004;
130:1-7.
17. van Dalen EC, Caron HN, Dickinson HO,
Kremer LC. Cardioprotective interventions
for  cancer  patients  receiving  anthracy-
clines.  Cochrane  Database  Syst  Rev
2008:CD003917.
18. Ewer MS, Martin FJ, Henderson C, et al.
Cardiac safety of liposomal anthracyclines.
Semin Oncol 2004;31:161-81.
19. Swenson CE, Bolcsak LE, Batist G, et al.
Figure  3.  Overall  survival
(OS) of patients with follic-
ular  lymphoma  who  had
received chemotherapy regi-
mens  containing  doxoru-
bicin and those who had not
received  this  anthracy-
cline.28 Reprinted with per-
mission  from  Rigacci  L  et
al.  The  role  of  anthracy-
clines  in  combination  che  -
mo    therapy  for  the  treat-
ment  of  follicular  lym-
phoma:  retrospective  study
of the Intergruppo Italiano
Linfomi on 761 cases. Leuk
Lymphoma  2003;44:1911-
17.
[page 12] [Hematology Reports 2011; 3(s3):e4]
Article[Hematology Reports 2011; 3(s3):e4] [page 13]
Pharmacokinetics of doxorubicin adminis-
tered i.v. as Myocet (TLC D-99; liposome-
encapsulated  doxorubicin  citrate)  com-
pared with conventional doxorubicin when
given  in  combination  with  cyclophos-
phamide  in  patients  with  metastatic
breast cancer. Anticancer Drugs 2003;14:
239-46.
20. Allen TM, Martin FJ. Advantages of lipo-
somal delivery systems for anthracyclines.
Semin Oncol 2004;31:5-15.
21. Potchoiba  MJ,  West  M,  Smolarek  TA,
Macaione G, Santacroce E, Lundeen GR.
Tissue distribution of doxorubicin in the
free and liposomal forms in male Beagles.
Proc  Am  Assoc  Cancer  Res  1996;37:392:
Abs 2675.
22. Federico M, Iannone A, Chan HC, Magin
RL. Bone marrow uptake of liposome-en-
trapped spin label after liver blockade with
empty liposomes. Magn Reson Med 1989;
10:418-25.
23. Levine AM, Tulpule A, Espina B, et al. Lipo-
some-encapsulated doxorubicin in combi-
nation  with  standard  agents  (cyclophos-
phamide, vincristine, prednisone) in pa-
tients with newly diagnosed AIDS-related
non-Hodgkin’s  lymphoma:  results  of
therapy and correlates of response. J Clin
Oncol 2004;22:2662-70.
24. Tulpule  A,  Espina  BM,  Berman  N,  et  al.
Phase I/II trial of nonpegylated liposomal
doxorubicin,  cyclophosphamide,  vin-
cristine, and prednisone in the treatment
of  newly  diagnosed  aggressive  non-
Hodgkin’s  lymphoma.  Clin  Lymphoma
Myeloma 2006;7:59-64.
25. Zaja  F,  Tomadini  V,  Zaccaria  A,  et  al.
CHOP-rituximab with pegylated liposomal
doxorubicin  for  the  treatment  of  elderly
patients  with  diffuse  large  B-cell  lym-
phoma. Leuk Lymphoma 2006;47:2174-80.
26 Rigacci L, Mappa S, Nassi L, et al. Lipo-
some-encapsulated doxorubicin in combi-
nation  with  cyclophosphamide,  vin-
cristine, prednisone and rituximab in pa-
tients with lymphoma and concurrent car-
diac diseases or pre-treated with anthracy-
clines. Hematol Oncol 2007;25:198-203.
27. Luminari S, Montanini A, Caballero D, et
al.  Nonpegylated  liposomal  doxorubicin
(MyocetTM)  combination  (R-COMP)  che  -
motherapy in elderly patients with diffuse
large  B-cell  lymphoma  (DLBCL):  results
from the phase II EUR018 trial. Ann Oncol
2010;21:1492-9.
28. Rigacci L, Federico M, Martelli M, et al.
The role of anthracyclines in combination
chemotherapy for the treatment of follic-
ular lymphoma: retrospective study of the
Intergruppo Italiano Linfomi on 761 cases.
Leuk Lymphoma 2003;44:1911-17.
29. Iannitto E, Luminari S, Mammi C, et al.
Non-pegylated lyposomal doxorubicin, cy-
clophosphamide,  vincristine,  prednisone
and rituximab (R-COMP) as initial treat-
ment  for  patients  with  splenic  marginal
zone  lymphoma  (SMZL):  a  GISL  study.
Blood 2007;110:Abs 1293.
Article